Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 16,316 shares of RNA stock, worth $601,734. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,316
Previous 15,570
4.79%
Holding current value
$601,734
Previous $459,000
0.87%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RNA
# of Institutions
243Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$421 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$418 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$357 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$341 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$323 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.92B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...